Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Change in Acquisitions & Divestments (2024 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments rose 200.15% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, up 173.84% year-over-year, with the annual reading at $12.0 million for FY2025, N/A changed from the prior year.
  • Change in Acquisitions & Divestments hit $6.0 million in Q4 2025 for Vistagen Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $8.0 million in Q2 2025 to a low of $2.0 million in Q4 2024.